Story preview
Topics in this story
Continue reading on the publisher site for the full article.
Read on publisher →The Motley Fool
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
4
in the last 3 days
First reported
2 days ago
3 outlets since
Countries
3 other outlets reported this story in the last 3 days.
AbbVie Inc. (NYSE:ABBV) closed at $262.82 on October 2, and Bristol Myers Squibb Company (NYSE:BMY) at $61.15. Both spent the last few years doing the same difficult thing. Replacing a drug that was about to lose its patent with something new, before the revenue disappeared. AbbVie is widely seen as having pulled it…
AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.
Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.